The amyloid cascade hypothesis provides an economical mechanistic explanation for Alzheimer's disease (AD) dementia and correlated neuropathology. However, some nonagenarian individuals (high pathology controls, HPC) remain cognitively intact while enduring high amyloid plaque loads for decades. If amyloid accumulation is the prime instigator of neurotoxicity and dementia, specific protective mechanisms must enable these HPC to evade cognitive decline. We evaluated the neuropathological and biochemical differences existing between non-demented (ND)-HPC and an age-matched cohort with AD dementia. The ND-HPC selected for our study were clinically assessed as ND and possessed high amyloid plaque burdens. ELISA and Western blot analyses were used to quantify a group of proteins related to APP/Aβ/tau metabolism and other neurotrophic and inflammation-related molecules that have been found to be altered in neurodegenerative disorders and are pivotal to brain homeostasis and mental health. The molecules assumed to be critical in AD dementia, such as soluble or insoluble Aβ40, Aβ42 and tau were quantified by ELISA. Interestingly, only Aβ42 demonstrated a significant increase in ND-HPC when compared to the AD group. The vascular amyloid load which was not used in the selection of cases, was on the average almost 2-fold greater in AD than the ND-HPC, suggesting that a higher degree of microvascular dysfunction and perfusion compromise was present in the demented cohort. Neurofibrillary tangles were less frequent in the frontal cortices of ND-HPC. Biochemical findings included elevated vascular endothelial growth factor, apolipoprotein E and the neuroprotective factor S100B in ND-HPC, while anti-angiogenic pigment epithelium derived factor levels were lower. The lack of clear Aβ-related pathological/biochemical demarcation between AD and ND-HPC suggests that in addition to amyloid plaques other factors, such as neurofibrillary tangle density and vascular integrity, must play important roles in cognitive failure.
References
[1]
Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56: 484–546.
[2]
Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH (2010) Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 67: 114–121.
[3]
Kobayashi M, Sato T, Sato A, Imamura T (2009) [Oldest-old dementia in a Japanese memory clinic]. Brain Nerve 61: 972–978.
[4]
Kawas CH, Corrada MM (2006) Alzheimer's and dementia in the oldest-old: a century of challenges. Curr Alzheimer Res 3: 411–419.
[5]
von Gunten A, Ebbing K, Imhof A, Giannakopoulos P, Kovari E (2010) Brain aging in the oldest-old. Curr Gerontol Geriatr Res 2010: 358531.
[6]
Kinsella K, He W (2009) An Aging World: 2008 International Population Reports, U.S. Government Printing Office. Available: http://www.census.gov/prod/2009pubs/p95-？09-1.pdf.
[7]
Selkoe DJ (1989) Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58: 611–612.
[8]
Korczyn AD (2008) The amyloid cascade hypothesis. Alzheimers Dement 4: 176–178.
[9]
Plassman BL, Khachaturian AS, Townsend JJ, Ball MJ, Steffens DC, et al. (2006) Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimers Dement 2: 2–11.
[10]
Jellinger KA (1995) Alzheimer's changes in non-demented and demented patients. Acta Neuropathol 89: 112–113.
[11]
Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68: 270–281.
[12]
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572–580.
[13]
Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, et al. (2011) Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology. Arch Neurol.
[14]
Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, et al. (2010) Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 223: 334–346.
[15]
Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, et al. (2010) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6: 230–238.
[16]
Quigley H, Colloby SJ, O'Brien JT (2010) PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 26(10): 991–999.
[17]
Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al. (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355–1365.
[18]
Beach TG, Sue LI, Walker DG, Roher AE, Lue L, et al. (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 9: 229–245.
[19]
Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56: 1095–1097.
[20]
Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 18: S91–S94.
[21]
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479–486.
[22]
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239–259.
[23]
Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31: 545–548.
[24]
Mulugeta E, Molina-Holgado F, Elliott MS, Hortobagyi T, Perry R, et al. (2008) Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. Dement Geriatr Cogn Disord 25: 278–286.
[25]
Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, et al. (2011) Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32: 791–801.
[26]
Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, et al. (2003) Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 61: 487–492.
[27]
Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, et al. (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63: 204–212.
[28]
de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, et al. (2010) Caspase activation precedes and leads to tangles. Nature 464: 1201–1204.
[29]
Gray EG, Paula-Barbosa M, Roher A (1987) Alzheimer's disease: paired helical filaments and cytomembranes. Neuropathol Appl Neurobiol 13: 91–110.
[30]
Goux WJ, Rodriguez S, Sparkman DR (1995) Analysis of the core components of Alzheimer paired helical filaments. A gas chromatography/mass spectrometry characterization of fatty acids, carbohydrates and long-chain bases. FEBS Lett 366: 81–85.
[31]
Goux WJ, Rodriguez S, Sparkman DR (1996) Characterization of the glycolipid associated with Alzheimer paired helical filaments. J Neurochem 67: 723–733.
[32]
Jefferson AL, Tate DF, Poppas A, Brickman AM, Paul RH, et al. (2007) Lower cardiac output is associated with greater white matter hyperintensities in older adults with cardiovascular disease. J Am Geriatr Soc 55: 1044–1048.
[33]
Jefferson AL, Himali JJ, Beiser AS, Au R, Massaro JM, et al. (2010) Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation 122: 690–697.
[34]
Belohlavek M, Jiamsripong P, Calleja AM, McMahon EM, Maarouf CL, et al. (2009) Patients with Alzheimer disease have altered transmitral flow: echocardiographic analysis of the vortex formation time. J Ultrasound Med 28: 1493–1500.
[35]
Roher AE, Garami Z, Tyas SL, Maarouf CL, Kokjohn TA, et al. (2011) Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease. Alzheimers Dement 7: 445–455.
[36]
Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, et al. (2011) Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement 7: 436–444.
[37]
Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, et al. (2003) Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 9: 112–122.
[38]
Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, et al. (2004) Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 26: 525–539.
[39]
Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF (2009) Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 215: 5–19.
[40]
Lue LF, Kuo YM, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol 41: 115–128.
[41]
Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25: 1439–1451.
Kashon ML, Ross GW, O'Callaghan JP, Miller DB, Petrovitch H, et al. (2004) Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis 6: 595–604.
[44]
Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttila T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis 20: 858–870.
[45]
Mattson MP (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77: 1081–1132.
[46]
Schettini G, Govoni S, Racchi M, Rodriguez G (2010) Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role–relevance for Alzheimer pathology. J Neurochem 115: 1299–1308.
[47]
Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1–32.
[48]
Slunt HH, Thinakaran G, Von Koch C, Lo AC, Tanzi RE, et al. (1994) Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP). J Biol Chem 269: 2637–2644.
[49]
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352–357.
[50]
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486–489.
[51]
Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, et al. (2000) Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem 275: 21099–21106.
[52]
Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29: 12787–12794.
[53]
Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, et al. (2008) The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis. J Biol Chem 283: 17039–17048.
[54]
Perez A, Morelli L, Cresto JC, Castano EM (2000) Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25: 247–255.
[55]
Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, et al. (2004) Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem 279: 56004–56013.
[56]
de Tullio MB, Morelli L, Castano EM (2008) The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective. Prion 2: 51–56.
[57]
Shinall H, Song ES, Hersh LB (2005) Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 44: 15345–15350.
[58]
Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26: 645–654.
[59]
Muntane G, Dalfo E, Martinez A, Ferrer I (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152: 913–923.
[60]
Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103: 5644–5651.
[61]
Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, et al. (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76: 1091–1098.
[62]
Mahley RW, Huang Y, Weisgraber KH (2007) Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 4: 537–540.
[63]
Tanskanen M, Lindsberg PJ, Tienari PJ, Polvikoski T, Sulkava R, et al. (2005) Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype. Neuropathol Appl Neurobiol 31: 589–599.
[64]
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, et al. (2011) Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance. Science Translational Medicine 3: 89ra57.
[65]
Kalaria RN (2002) Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis 13: Suppl 248–52.
[66]
Grammas P, Yamada M, Zlokovic B (2002) The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 4: 217–223.
[67]
Kalaria RN (2010) Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 68: Suppl 2S74–S87.
[68]
Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, et al. (1998) Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 62: 101–105.
[69]
Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis 10: 111–118.
[70]
Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, et al. (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25: 283–290.
[71]
Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26: 943–954.
[72]
Hai J, Li ST, Lin Q, Pan QG, Gao F, et al. (2003) Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery 53: 963–970.
[73]
Gora-Kupilas K, Josko J (2005) The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 43: 31–39.
[74]
Paris D, Townsend K, Quadros A, Humphrey J, Sun J, et al. (2004) Inhibition of angiogenesis by Abeta peptides. Angiogenesis 7: 75–85.
[75]
Tombran-Tink J, Shivaram SM, Chader GJ, Johnson LV, Bok D (1995) Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 15: 4992–5003.
[76]
Chader GJ (2001) PEDF: Raising both hopes and questions in controlling angiogenesis. Proc Natl Acad Sci U S A 98: 2122–2124.
[77]
Yamagishi S, Inagaki Y, Takeuchi M, Sasaki N (2004) Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease? Med Hypotheses 63: 115–117.
[78]
Rychli K, Huber K, Wojta J (2009) Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 13: 1295–1302.
[79]
Yabe T, Sanagi T, Yamada H (2010) The neuroprotective role of PEDF: implication for the therapy of neurological disorders. Curr Mol Med 10: 259–266.
[80]
Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, et al. (1999) Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 58: 719–728.
[81]
Bilak MM, Becerra SP, Vincent AM, Moss BH, Aymerich MS, et al. (2002) Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci 22: 9378–9386.
[82]
Abramson LP, Stellmach V, Doll JA, Cornwell M, Arensman RM, et al. (2003) Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatr Surg 38: 336–342.
[83]
Tombran-Tink J, Barnstable CJ (2003) Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 9: 244–250.
[84]
Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, et al. (2003) Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9: 774–780.
[85]
Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, et al. (2004) Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 164: 1225–1232.
[86]
Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, et al. (2004) Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A 101: 6605–6610.
[87]
Sawant S, Aparicio S, Tink AR, Lara N, Barnstable CJ, et al. (2004) Regulation of factors controlling angiogenesis in liver development: a role for PEDF in the formation and maintenance of normal vasculature. Biochem Biophys Res Commun 325: 408–413.
[88]
Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, et al. (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189: 323–333.
[89]
Duh EJ, Yang HS, Haller JA, De JE, Humayun MS, et al. (2004) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 137: 668–674.
[90]
Jin J, Guan M, Sima J, Gao G, Zhang M, et al. (2003) Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22: 473–477.
[91]
Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, et al. (2004) Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170: 242–251.
[92]
Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28: 155–163.
[93]
Maarouf CL, Andacht TM, Kokjohn TA, Castano EM, Sue LI, et al. (2009) Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res 6: 399–406.
[94]
Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10: 209–219.
[95]
Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5: 311–322.
[96]
Mowla SJ, Farhadi HF, Pareek S, Atwal JK, Morris SJ, et al. (2001) Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 276: 12660–12666.
[97]
Pinto S, Vlahovicek K, Buratti E (2011) PRO-MINE: A bioinformatics repository and analytical tool for TARDBP mutations. Hum Mutat 32: E1948–E1958.
[98]
Wilson AC, Dugger BN, Dickson DW, Wang DS (2011) TDP-43 in aging and Alzheimer's disease - a review. Int J Clin Exp Pathol 4: 147–155.
[99]
Chen-Plotkin AS, Lee VM, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6: 211–220.
[100]
McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, et al. (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69: 918–929.
[101]
Caccamo A, Magri A, Oddo S (2010) Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Abeta oligomers accumulation. Mol Neurodegener 5: 51.
[102]
Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, et al. (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 61: 435–445.
[103]
Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA (1991) Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 138: 235–246.
[104]
McMahon HT, Bolshakov VY, Janz R, Hammer RE, Siegelbaum SA, et al. (1996) Synaptophysin, a major synaptic vesicle protein, is not essential for neurotransmitter release. Proc Natl Acad Sci U S A 93: 4760–4764.
[105]
Schmitt U, Tanimoto N, Seeliger M, Schaeffel F, Leube RE (2009) Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. Neuroscience 162: 234–243.
Rothermundt M, Peters M, Prehn JH, Arolt V (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60: 614–632.
[108]
Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, et al. (2008) S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 12: 914–927.
[109]
Stroick M, Fatar M, Ragoschke-Schumm A, Fassbender K, Bertsch T, et al. (2006) Protein S-100B–a prognostic marker for cerebral damage. Curr Med Chem 13: 3053–3060.
[110]
Mrak RE, Griffin WS (2001) The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging 22: 915–922.
[111]
Van Eldik LJ, Griffin WS (1994) S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim Biophys Acta 1223: 398–403.
[112]
Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ (2001) Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 39: 409–413.
[113]
Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, et al. (2003) Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett 336: 167–170.
[114]
Mori T, Asano T, Town T (2010) Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease. Cardiovasc Psychiatry Neurol. 2010.
[115]
Serbinek D, Ullrich C, Pirchl M, Hochstrasser T, Schmidt-Kastner R, et al. (2010) S100b counteracts neurodegeneration of rat cholinergic neurons in brain slices after oxygen-glucose deprivation. Cardiovasc Psychiatry Neurol. 2010. (106123).
[116]
Spilt A, Weverling-Rijnsburger AW, Middelkoop HA, van Der Flier WM, Gussekloo J, et al. (2005) Late-onset dementia: structural brain damage and total cerebral blood flow. Radiology 236: 990–995.
[117]
Maalikjy Akkawi N, Borroni B, Agosti C, Pezzini A, Magoni M, et al. (2003) Volume reduction in cerebral blood flow in patients with Alzheimer's disease: a sonographic study. Dement Geriatr Cogn Disord 16: 163–169.
[118]
Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, et al. (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41: 11080–11090.
[119]
Postiglione A, Lassen NA, Holman BL (1993) Cerebral blood flow in patients with dementia of Alzheimer's type. Aging (Milano) 5: 19–26.
[120]
Streitparth F, Wieners G, Kamena A, Schroder RJ, Stiepani H, et al. (2008) [Diagnostic value of multislice perfusion CT in dementia patients]. Radiologe 48: 175–183.
[121]
Kobayashi S, Tateno M, Utsumi K, Takahashi A, Saitoh M, et al. (2008) Quantitative analysis of brain perfusion SPECT in Alzheimer's disease using a fully automated regional cerebral blood flow quantification software, 3DSRT. J Neurol Sci 264: 27–33.
[122]
Nishimura T, Hashikawa K, Fukuyama H, Kubota T, Kitamura S, et al. (2007) Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study. Ann Nucl Med 21: 15–23.
[123]
Matsuda H, Kanetaka H, Ohnishi T, Asada T, Imabayashi E, et al. (2002) Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 29: 1502–1505.
